PMID- 27123183
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160428
LR  - 20220331
IS  - 2001-6689 (Print)
IS  - 2001-6689 (Electronic)
IS  - 2001-6689 (Linking)
VI  - 3
DP  - 2015
TI  - Efficacy, tolerability, and safety of aripiprazole once-monthly versus other 
      long-acting injectable antipsychotic therapies in the maintenance treatment of 
      schizophrenia: a mixed treatment comparison of double-blind randomized clinical 
      trials.
LID - 10.3402/jmahp.v3.27208 [doi]
AB  - BACKGROUND: Treatment with long-acting injectable (LAI) antipsychotic medication 
      is an important element of relapse prevention in schizophrenia. Recently, the 
      intramuscular once-monthly formulation of aripiprazole received marketing 
      approval in Europe and the United States for schizophrenia. OBJECTIVE: This study 
      aimed to compare aripiprazole once-monthly with other LAI antipsychotics in terms 
      of efficacy, tolerability, and safety. DATA SOURCES: A systematic literature 
      review was conducted to identify relevant double-blind randomized clinical trials 
      of LAIs conducted in the maintenance treatment of schizophrenia. MEDLINE, MEDLINE 
      In-Process, Embase, the Cochrane Library, PsycINFO, conference proceedings, 
      clinical trial registries, and the reference lists of key review articles were 
      searched. The literature search covered studies dating from January 2002 to May 
      2013. STUDY SELECTION: Studies were required to have >/=24 weeks of follow-up. 
      Patients had to be stable at randomization. Studies were not eligible for 
      inclusion if efficacy of acute and maintenance phase treatment was not reported 
      separately. Six trials were identified (0.5% of initially identified studies), 
      allowing comparisons of aripiprazole once-monthly, risperidone LAI, paliperidone 
      palmitate, olanzapine pamoate, haloperidol depot, and placebo. DATA EXTRACTION: 
      Data extracted included study details, study duration, the total number of 
      patients in each treatment arm, efficacy, tolerability, and safety outcomes. The 
      efficacy outcome contained the number of patients that experienced a relapse, 
      tolerability outcomes included the number of patients that discontinued treatment 
      due to treatment-related adverse events (AEs), and that discontinued treatment 
      due to reasons other than AEs (e.g., loss to follow-up). Safety outcomes included 
      the incidence of clinically relevant weight gain and extrapyramidal symptoms. 
      DATA SYNTHESIS: Data were analyzed by applying a mixed treatment comparison 
      competing risks model (efficacy) and using binary models (safety). There was no 
      statistically significant difference between any study outcome, including the 
      risk of relapse, the risk of discontinuations, and safety outcomes. CONCLUSIONS: 
      Aripiprazole once-monthly is similarly efficacious to other LAIs with relatively 
      low rates of discontinuation due to AEs and due to reasons other than AEs than 
      other LAIs.
FAU - Majer, Istvan M
AU  - Majer IM
AD  - Pharmerit International, Rotterdam, The Netherlands.
FAU - Gaughran, Fiona
AU  - Gaughran F
AD  - National Psychosis Service, South London and Maudsley NHS Foundation Trust, 
      London, United Kingdom; The Institute of Psychiatry, Psychology and Neuroscience, 
      King's College, London, United Kingdom.
FAU - Sapin, Christophe
AU  - Sapin C
AD  - Global Analytics, Lundbeck SAS, Paris, France.
FAU - Beillat, Maud
AU  - Beillat M
AD  - Global Health Economics & Outcomes Research, Lundbeck SAS, Paris, France.
FAU - Treur, Maarten
AU  - Treur M
AD  - Pharmerit International, Rotterdam, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20150910
PL  - Switzerland
TA  - J Mark Access Health Policy
JT  - Journal of market access & health policy
JID - 101670174
PMC - PMC4802697
OTO - NOTNLM
OT  - efficacy
OT  - long-acting injectable antipsychotics
OT  - maintenance treatment
OT  - mixed treatment comparison
OT  - safety
OT  - schizophrenia
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
PMCR- 2015/09/10
CRDT- 2016/04/29 06:00
PHST- 2015/01/12 00:00 [received]
PHST- 2015/07/24 00:00 [revised]
PHST- 2015/07/28 00:00 [accepted]
PHST- 2016/04/29 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
PHST- 2015/09/10 00:00 [pmc-release]
AID - 27208 [pii]
AID - 10.3402/jmahp.v3.27208 [doi]
PST - epublish
SO  - J Mark Access Health Policy. 2015 Sep 10;3. doi: 10.3402/jmahp.v3.27208. 
      eCollection 2015.